Editorial

45 years of Seminars in Thrombosis and Hemostasis

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹¹ Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia

Semin Thromb Hemost 2018;44:407–416.

Seminars in Thrombosis and Hemostasis (STH) has been publishing papers since 1974. The year 2018 therefore marks the 45th year of publication for STH. STH began its life under the leadership of its founding Editor in Chief (EIC), Eberhard F. Mammen, who sadly passed away in 2008,¹ at which time I took over the reins as EIC. The year 2018 therefore also marks the 10th year anniversary of my time as EIC. Some of the history around STH was published as part of our 40th year anniversary celebrations in 2014.^{2,3} STH started with four issues per year, publishing around 300 to 400 print pages per year. STH grew to six issues per year in 1996, then publishing around 500 to 700 pages per year. Another change in 2006 saw STH publishing eight issues per year, and around 800 to 1,000 pages per year. Every year since then, STH has continued with eight issues, and around 800 to 1,000 print pages (►Fig. 1).

As mentioned, STH celebrated its 40th year anniversary with two special issues in 2014.^{2,3} It is expected that another celebratory issue will be published to celebrate the 50th year anniversary of STH in 2024. Although it is too early to

consider a celebratory issue within 2018, I did feel the need to mark the special occasion of “45 years in production” in a way befitting of the journal, including its founding “fathers.” Accordingly, I decided to gather and share some data with the readership. One set of data that I collected and updated was our annual page output, as shown in ►Fig. 1. As noted, STH is now printing around 900 pages per year, reaching a peak very close to (but never exceeding) 1,000 pages in 2011 and 2013. These data were easy to collect. As noted in several past Editorials, STH also has access to other metrics that are used to assess the relevance of our publications. The first is download data, which can be considered a marker of content “popularity,” essentially reflecting how many times a particular item published in STH has been accessed online by the readership. These data are also used to determine the winners of the STH Eberhard F. Mammen “Most Popular” papers, the last announcement for which was made earlier in 2018.⁴ Another metric we assess is citation data, in particular that provided by Journal Citation Reports, the basis for the well-known “Impact Factor” metric. This in part forms the basis of our “Welcome” editorials, the last announcement for which (2016 Impact Factor) was also made earlier in 2018.⁵ This metric perhaps reflects the “relevance” of STH content to other subsequent publishing authors, essentially reflecting how many times a particular item has been cited by other authors, albeit as limited to the Thomson citation database. Naturally, there are also other metrics that can be assessed,⁶ including, for example, Google Scholar (<https://scholar.google.com/intl/en-US/scholar/about.html>). However, as the well-known adage goes: “The best-laid plans of mice and men often go awry.”

I was easily able to identify the top cited papers published in STH according to Google Scholar. Given this is the 45th year of publication, I have listed the top 45 cited papers published in STH (according to Google Scholar) in ►Table 1. A review of the data, however, identifies some limitations. The earliest paper cited in this dataset was published in 1982 (and not 1974 when

Fig. 1 *Seminars in Thrombosis and Hemostasis*. Number of issues and number of pages published per year from 1974 to 2017 inclusive.

Address for correspondence
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme Recent Developments in Antiphospholipid Antibodies and the Antiphospholipid Syndrome; **Guest Editor:** Rolf T. Urbanus, PhD.

Copyright © 2018 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <https://doi.org/10.1055/s-0038-1657762>.
ISSN 0094-6176.

Table 1 The 45 top cited papers published in *Seminars in Thrombosis and Hemostasis* according to Google Scholar^a

Rank	Citation	Citations (n)	Year of publication	Citations / year	Rank (C/Y)
1	Rodgers RP, Levin J. A critical reappraisal of the bleeding time. <i>Semin Thromb Hemost</i> 1990;16(1):1–20	773	1990	28.6	6
2	Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. <i>Semin Thromb Hemost</i> 2003;29(5):435–450	657	2003	46.9	1
3	Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer–PFA-100. <i>Semin Thromb Hemost</i> 1995;21 (Suppl 2):106–112	517	1995	23.5	12
4	Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. <i>Semin Thromb Hemost</i> 1998;24(2):195–202	459	1998	24.2	10
5	Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. <i>Semin Thromb Hemost</i> 1999;25(Suppl 3):5–16.	424	1999	23.6	11
6	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. <i>Semin Thromb Hemost</i> 2005;31(4):381–392	391	2005	32.6	3
7	Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. <i>Semin Thromb Hemost</i> 1998;24 (1):33–44	372	1998	19.6	19
8	Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y ₁₂ adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. <i>Semin Thromb Hemost</i> 2005;31(2):174–183	367	2005	30.6	4
9	Hellgren M. Hemostasis during normal pregnancy and puerperium. <i>Semin Thromb Hemost</i> 2003;29(2):125–130	357	2003	25.5	7
10	Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, Selik NR, Wilson RF. Hemostasis changes during cardiopulmonary bypass surgery. <i>Semin Thromb Hemost</i> 1985;11(3):281–292	352	1985	11.0	34
11	Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. <i>Semin Thromb Hemost</i> 1999;25(2):173–182	333	1999	18.5	20
12	Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, Gries FA. Large platelets circulate in an activated state in diabetes mellitus. <i>Semin Thromb Hemost</i> 1991;17(4):433–438	306	1991	11.8	31
13	Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. <i>Semin Thromb Hemost</i> 1999;25(Suppl 2):15–19	298	1999	16.6	23
14	Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. <i>Semin Thromb Hemost</i> 2000;26(3):219–25.	298	2000	17.5	21
15	Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. <i>Semin Thromb Hemost</i> 2004;30(5):579–589	293	2004	22.5	16
16	Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y ₁₂ receptor antagonist activity. <i>Semin Thromb Hemost</i> 2005 Apr;31(2):184–94.	276	2005	23.0	13
17	van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y ₁₂ antagonists. <i>Semin Thromb Hemost</i> 2005;31(2):195–204	276	2005	23.0	14
18	Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. <i>Semin Thromb Hemost</i> 1997;23(4):349–356	273	1997	13.7	26
19	Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. <i>Semin Thromb Hemost</i> 1991 Jul;17(3):303–12.	259	1991	10.0	36
20	Bick RL. Coagulation abnormalities in malignancy: a review. <i>Semin Thromb Hemost</i> 1992;18(4):353–372	258	1992	10.3	35
21	Esmon CT. Inflammation and the activated protein C anticoagulant pathway. <i>Semin Thromb Hemost</i> 2006;32(Suppl 1):49–60	252	2006	22.9	15
22	Clauss M. Molecular biology of the VEGF and the VEGF receptor family. <i>Semin Thromb Hemost</i> 2000;26(5):561–569	247	2000	14.5	25
23	Bick RL. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. <i>Semin Thromb Hemost</i> 1985;11(3):249–280	245	1985	7.7	40
24	Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. <i>Semin Thromb Hemost</i> 2010;36(3):321–331	240	2010	34.3	2

Table 1 (Continued)

Rank	Citation	Citations (n)	Year of publication	Citations / year	Rank (C/Y)
25	Bachmann F, Kruithof IE. Tissue plasminogen activator: chemical and physiological aspects. <i>Semin Thromb Hemost</i> 1984;10(1):6–17	238	1984	7.2	42
26	De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. <i>Semin Thromb Hemost</i> 1998;24(4):367–79.	238	1998	12.5	29
27	Østerud B, Bjørklid E. Sources of tissue factor. <i>Semin Thromb Hemost</i> 2006;32(1):11–23	234	2006	21.3	17
28	Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. <i>Semin Thromb Hemost</i> 1999;25(2):137–145	233	1999	12.9	28
29	Bick RL. Disseminated intravascular coagulation and related syndromes: a clinical review. <i>Semin Thromb Hemost</i> 1988;14(4):299–338	230	1988	7.9	39
30	Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. <i>Semin Thromb Hemost</i> 2008;34(3):236–250	228	2008	25.3	8
31	Favaloro EJ. Clinical utility of the PFA-100. <i>Semin Thromb Hemost</i> 2008;34(8):709–733	227	2008	25.2	9
32	Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. <i>Semin Thromb Hemost</i> 2004;30(1):95–108	227	2004	17.5	22
33	Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. <i>Semin Thromb Hemost</i> 2006;32 (Suppl 1):32–38	226	2006	20.5	18
34	Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. <i>Semin Thromb Hemost</i> 2000;26(3):341–348	224	2000	13.2	27
35	Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. <i>Semin Thromb Hemost</i> 2002;28(Suppl 2):3–13	224	2002	14.9	24
36	Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. <i>Semin Thromb Hemost</i> 1992;18(1):104–116	222	1992	8.9	37
37	Caprini JA, Arcelus JL, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. <i>Semin Thromb Hemost</i> 1991;17(Suppl 3):304–312	220	1991	8.5	38
38	Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. <i>Semin Thromb Hemost</i> 1999;25(Suppl 2):25–28	219	1999	12.2	30
39	Fenton JW II. Regulation of thrombin generation and functions. <i>Semin Thromb Hemost</i> 1988;14(3):234–240	218	1998	11.5	33
40	Bevilacqua MP, Gimbrone MA Jr. Inducible endothelial functions in inflammation and coagulation. <i>Semin Thromb Hemost</i> 1987;13(4):425–433	203	1987	6.8	44
41	Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. <i>Semin Thromb Hemost</i> 1990;16(3):207–216	202	1990	7.5	41
42	Rak J. Microparticles in cancer. <i>Semin Thromb Hemost</i> 2010;36(8):888–906	201	2010	28.7	5
43	van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. <i>Semin Thromb Hemost</i> 2000;26(3):281–289	200	2000	11.8	32
44	Kelton JG, Gibbons S. Autoimmune platelet destruction: idiopathic thrombocytopenic purpura. <i>Semin Thromb Hemost</i> 1982;8(2):83–104	195	1982	5.6	45
45	Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. <i>Semin Thromb Hemost</i> 1990;16(4):299–309	194	1990	7.2	43

^aTable identifies number of citations identified by Google Scholar (<https://scholar.google.com/intl/en-US/scholar/about.html>), accordant ranking of citations, year of publication, average number of citations per year (based on year published), and “re-ranking” based on averaged citations (citations/year; C/Y). Date range of publications 1982–2010.

STH began). Google Scholar does not identify how far back its records go, either for published papers or for the citing material. Thus, this citation list (► **Table 1**) will likely not fully identify all the past publications from STH, nor all the subsequent citing papers. Essentially, the data are reflective only of papers published from 1982. Nonetheless, it does provide some sort of guide, as well as providing the backdrop to some interesting facts. The top cited paper according to Google

Scholar was “A critical reappraisal of the bleeding time.”⁷ This is interesting not only because this test is no longer performed by most developed countries. Indeed, the skin bleeding time was once one of the all-time favorite of pre-surgical requests. Also of interest was that the founding editor of STH, Eberhard Mammen, has two papers listed in ► **Table 1**, the first of which was on a then new instrument, the PFA-100.⁸ This was not, of course, the first paper published on the PFA-

Table 2 The 45 top cited papers published in *Seminars in Thrombosis and Hemostasis* according to Journal Citation Reports, the basis of the well-known "Impact Factor"^a

Rank	Citation	Citations (n)	Year of publication	Citations / year	Rank (C/Y)
1	Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. <i>Semin Thromb Hemost</i> 2003;29(5):435–450	376	2003	26.9	1
2	Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. <i>Semin Thromb Hemost</i> 1998;24(2):195–202	328	1998	17.3	5
3	Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. <i>Semin Thromb Hemost</i> 1999;25(Suppl 3):5–16	244	1999	13.6	16
4	Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y ₁₂ adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. <i>Semin Thromb Hemost</i> 2005;31(2):174–183	222	2005	18.5	2
5	Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. <i>Semin Thromb Hemost</i> 2000;26(3):219–225	205	2000	12.1	19
6	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. <i>Semin Thromb Hemost</i> 2005;31(4):381–392	197	2005	16.4	7
7	Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y ₁₂ receptor antagonist activity. <i>Semin Thromb Hemost</i> 2005;31(2):184–194	192	2005	16.0	8
8	Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. <i>Semin Thromb Hemost</i> 1999;25(Suppl 2):15–19	190	1999	10.6	23
9	van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y ₁₂ antagonists. <i>Semin Thromb Hemost</i> 2005;31(2):195–204	188	2005	15.7	9
10	Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. <i>Semin Thromb Hemost</i> 1998;24(1):33–44	185	1998	9.7	26
11	Hellgren M. Hemostasis during normal pregnancy and puerperium. <i>Semin Thromb Hemost</i> 2003;29(2):125–130	181	2003	12.9	17
12	Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. <i>Semin Thromb Hemost</i> 1999;25(2):173–182	170	1999	9.4	27
13	Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. <i>Semin Thromb Hemost</i> 1997;23(4):349–356	169	1997	8.5	28
14	Esmon CT. Inflammation and the activated protein C anticoagulant pathway. <i>Semin Thromb Hemost</i> 2006;32(Suppl 1):49–60	169	2006	15.4	11
15	Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. <i>Semin Thromb Hemost</i> 2004;30(5):579–589	160	2004	12.3	18
16	Østerud B, Bjørklid E. Sources of tissue factor. <i>Semin Thromb Hemost</i> 2006;32(1):11–23	155	2006	14.1	14
17	Favaloro EJ. Clinical utility of the PFA-100. <i>Semin Thromb Hemost</i> 2008;34(8):709–733	153	2008	17.0	6
18	Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. <i>Semin Thromb Hemost</i> 2004;30(1):95–108	150	2004	11.5	20
19	Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. <i>Semin Thromb Hemost</i> 1999;25(Suppl 2):25–28	142	1999	7.9	29
20	Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. <i>Semin Thromb Hemost</i> 1999;25(2):137–145	134	1999	7.4	32
21	Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. <i>Semin Thromb Hemost</i> 1997;23(4):339–347	133	1997	6.7	35
22	Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. <i>Semin Thromb Hemost</i> 2005;31(2):217–233	133	2005	11.1	21
23	De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. <i>Semin Thromb Hemost</i> 1998;24(4):367–379	132	1998	6.9	33
24	Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. <i>Semin Thromb Hemost</i> 2000;26(3):341–348	131	2000	7.7	31

Table 2 (Continued)

Rank	Citation	Citations (n)	Year of publication	Citations / year	Rank (C/Y)
25	Rak J. Microparticles in cancer. <i>Semin Thromb Hemost</i> 2010;36(8):888–906	129	2010	18.4	3
26	Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. <i>Semin Thromb Hemost</i> 2010;36(3):321–331	128	2010	18.3	4
27	Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. <i>Semin Thromb Hemost</i> 2008;34(3):236–250	126	2008	14.0	15
28	De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. <i>Semin Thromb Hemost</i> 1997;23(5):411–418	117	1997	5.9	42
29	Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. <i>Semin Thromb Hemost</i> 2002;28(1):53–66	117	2002	7.8	30
30	Karimi M, Berczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. <i>Semin Thromb Hemost</i> 2009;35(4):426–438	117	2009	14.6	13
31	Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. <i>Semin Thromb Hemost</i> 2006;32(Suppl 1):61–8	115	2006	10.5	24
32	Francis JL, Biggerstaff J, Amirhosravi A. Hemostasis and malignancy. <i>Semin Thromb Hemost</i> 1998;24(2):93–109	114	1998	6.0	39
33	Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. <i>Semin Thromb Hemost</i> 1996;22(2):197–202	113	1996	5.4	45
34	Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz RP Jr. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. <i>Semin Thromb Hemost</i> 1997;23(6):503–516	113	1997	5.7	44
35	Clauss M. Molecular biology of the VEGF and the VEGF receptor family. <i>Semin Thromb Hemost</i> 2000;26(5):561–569	113	2000	6.6	36
36	Davie EW, Kulman JD. An overview of the structure and function of thrombin. <i>Semin Thromb Hemost</i> 2006;32(Suppl 1):3–15	110	2006	10.0	25
37	Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. <i>Semin Thromb Hemost</i> 2010;36(8):807–818	109	2010	15.6	10
38	Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. <i>Semin Thromb Hemost</i> 2007;33(4):313–320	107	2007	10.7	22
39	Gando S. Disseminated intravascular coagulation in trauma patients. <i>Semin Thromb Hemost</i> 2001;27(6):585–592	105	2001	6.6	37
40	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” <i>Semin Thromb Hemost</i> 2010;36(1):59–70	103	2010	14.7	12
41	Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. <i>Semin Thromb Hemost</i> 2000;26(Suppl 1):5–21	102	2000	6.0	40
42	Østerud B, Bjørklid E. The tissue factor pathway in disseminated intravascular coagulation. <i>Semin Thromb Hemost</i> 2001;27(6):605–617	102	2001	6.4	38
43	van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. <i>Semin Thromb Hemost</i> 2000;26(3):281–289	101	2000	5.9	41
44	Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. <i>Semin Thromb Hemost</i> 2002;28(Suppl 2):3–13	100	2002	6.7	34
45	Coppola A, Davi G, De Stefano V, Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. <i>Semin Thromb Hemost</i> 2000;26(3):243–254	99	2000	5.8	43

^aTable identifies number of citations identified by Journal Citation Reports, as provided by the publisher of STH, Thieme, accordant ranking of citations, year of publication, average number of citations per year (based on year published), and “re-ranking” based on averaged citations (citations/year; C/Y). Date range of publications 1996–2010.

100 in STH. Indeed, STH produced an entire issue around this instrument (and its predecessor, the Thrombostat 4000), as a supplement issue a few years earlier in 1995. One paper from this issue, the original “description” of the PFA-100,⁹ did make

the listing in ► **Table 1**. However, another paper in this issue on the PFA-100 by Eberhard Mammen¹⁰ did not. This history is of additional interest for many reasons. First, the original study published by Eberhard Mammen and colleagues in 1998,⁸ and

listed in ►Table 1, was pivotal for obtaining the Food and Drug Administration (FDA) approval required for its subsequent use in the United States. Second, yet another paper appears in this list (►Table 1) on the PFA-100,¹¹ but this time by an obscure author named Favaloro, who wrote this paper as a tribute to Eberhard Mammen, and as part of an entire tribute issue on the year of his passing.¹ For anyone interested in the subsequent history of the PFA-100, this instrument has recently been “updated” to the PFA-200,¹² although this model has not yet been released in the United States. I suspect the manufacturer, Siemens, has an FDA submission pending or in preparation. Also of interest to me is that several other “forebearers of STH” or “forebearers of modern hemostasis” are listed in ►Table 1: for example, Roger Bick, who was a contributing author of some 35 papers in STH, spanning a period of more than 30 years, from 1976 to 2008.¹³ Roger Bick, like Eberhard Mammen, also passed away in 2008.^{1,13} Also listed in ►Table 1 is Silvia Pierangeli, who sadly passed away in 2013,¹⁴ and Harold Roberts, who passed away in 2017.¹⁵ Lastly, a special mention to a perennial favorite in STH by the authorship pair of Jurk and Kehrel,¹⁶ having won one of the inaugural Eberhard F. Mammen Most Popular awards in 2009,¹⁷ and having appeared annually in all of our Most Popular award listings thereafter, including the last.⁴ To be fairer to authors of later publications, where total citations will notably be reduced simply based on later publication date, the listing in ►Table 1 also has data shown in columns providing a summary of citations/year, as well as a re-ranking based on this annually averaged citation rate.

As a second marker of “publication relevance” to other subsequent publishing authors, the publisher was requested to provide a listing of the most highly cited papers according to the Journal Citation Reports, the basis for the well-known “Impact Factor” metric. Again, the adage of “The best-laid plans of mice and men often go awry” prevailed. The listing provided by the publisher, limited to the top 45 cited papers, is identified in ►Table 2. This listing is even more “date-challenged” than the listing in ►Table 1. Thus, the earliest paper published in this listing is 1996. The citation date range for these data comprises citations collected between 1996 and 2018. Thus, this listing is even more contemporary than that of ►Table 1. Nonetheless, the data remain of interest. “A critical reappraisal of the bleeding time,”⁷ the leading paper in ►Table 1, does not appear in ►Table 2, perhaps reflective of the data timeline (1996 onward) more so than the different database used for data collection (the data in ►Table 2 reflect a more limited database than that for Google Scholar, ►Table 1). Eberhard Mammen’s paper on the PFA-100⁸ does appear on the list (►Table 2), as does my tribute paper published in 2008,¹¹ as well as the paper by Silvia Pierangeli,¹⁸ and the perennial favorite by Jurk and Kehrel,¹⁶ but none of the papers by Roger Bick is listed in ►Table 2. As I mentioned, it uses a more restricted timeline for data inclusion and a different (more limited) database than that used in ►Table 1.

Additional metrics for STH around Journal Citation Report data are provided in ►Fig. 2. STH publishes in the order of 80 to 100 full length papers per year, which is similar to the number of citable items published per year (as related to

Fig. 2 *Seminars in Thrombosis and Hemostasis* (STH). Data from Journal Citation Reports. (A) Number of citable items published per year, as related to impact factor (IF) calculations from 2003 to 2016 inclusive. This would presumably mostly relate to full length articles. STH publishes in the order of 80 to 100 full length papers per year. (B) Percentage of citable items cited per year, as related to IF calculations from 2003 to 2016 inclusive. The vast majority (typically >95% in most recent years) of “citable items” published in STH are cited by others within the timeframe of the IF captured metrics (i.e., subsequent 2 years). (C) STH impact factor from 2003 to 2016 inclusive.

Impact Factor calculations). The vast majority (typically >95% in most recent years) of “citable items” published in STH are cited by other authors within the timeframe of the Impact Factor captured metrics (i.e., subsequent 2 years).

As mentioned earlier also, STH has another metric; it uses and reports annually, potentially considered a marker of “popularity” among the STH readership, and namely the annual Eberhard Mammen Most Popular award listings, based on highest download data for the preceding two years of data. Thus, the 2018 Most Popular awards, as most recently announced,⁴ assesses download data for the years 2016 and 2017 inclusive. The publisher was asked to provide a listing of “most popular” papers of “all time” according to download data. Did I mention the adage: “The

best-laid plans of mice and men often go awry”? As often happens with IT systems, the publisher “updated” its IT system recently, and thus the download data have become limited to data available since that update. The listing of the 45 most popular papers in STH since this IT update, reflecting a 4-year period from the start date of January 2014 until end of December 2017, is given in ►Tables 3 and 4. These identify full length papers published in STH that are, respectively, “free to download/open access” and “not free to download.” However, the data are even more contemporary than that shown in ►Tables 1 and 2. Given that “free to download/open access” material has a substantial advantage over “not free to download” material (which is only available to STH subscribers), there are now two separate categories of Eberhard Mammen

Most Popular award.⁴ Indeed, the fact that material is “free to download/open access” makes this material available to everyone, and thus such material inevitably yields higher download data than other material. For example, although “free to download/open access” material comprises less than 15% of what STH publishes, it comprises nearly 50% of the data for the top 200 downloads between 2014 and 2017 (inclusive). Thus, the top 200 listing for 2014–2017 included 25 Prefaces. Given that each issue of STH has a Preface, and given eight issues of STH per year, this means that most Prefaces published in 2013–2016 (total $n = 32$) were listed, as were most Editorials published in the same period. Notably, Editorials and Prefaces are free to download. Also, as per the citation data shown in ►Tables 1 and 2, those papers published earlier in timeline

Table 3 The top 45 most downloaded “free to download/open access” full papers published in *Seminars in Thrombosis and Hemostasis* during the period 2014–2017 inclusive^a

Rank	Citation	Year of publication
1	Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. <i>Semin Thromb Hemost</i> 2014;40(2):163–171	2014
2	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” <i>Semin Thromb Hemost</i> 2010;36(1):59–70	2010
3	Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. <i>Semin Thromb Hemost</i> 2014;40(1):60–65	2014
4	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. <i>Semin Thromb Hemost</i> 2005;31(4):381–392	2005
5	Tufano A, Guida A, Dario Di Minno MN, Prisco D, Cerbone AM, Minno GD. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. <i>Semin Thromb Hemost</i> 2011;37(3):267–274	2011
6	Mariani G, Bernardi F. Factor VII deficiency. <i>Semin Thromb Hemost</i> 2009;35(4):400–406	2009
7	Rak J. Microparticles in cancer. <i>Semin Thromb Hemost</i> 2010;36(8):888–906	2010
8	Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. <i>Semin Thromb Hemost</i> 2012;38(7):673–682. doi:10.1055/s-0032-1326782	2012
9	Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin k antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. <i>Semin Thromb Hemost</i> 2015;41(2):208–227	2015
10	George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. <i>Semin Thromb Hemost</i> 2013;39(2):153–160	2013
11	Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. <i>Semin Thromb Hemost</i> 2014;40(1):106–114	2014
12	Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. <i>Semin Thromb Hemost</i> 2011;37(3):280–297	2011
13	Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. <i>Semin Thromb Hemost</i> 2015;41(1):49–60	2015
14	Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. <i>Semin Thromb Hemost</i> 2012;38(1):47–54	2012
15	de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. <i>Semin Thromb Hemost</i> 2013;39(6):585–595	2013
16	Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Gallus A, Hunt BJ, Hylek EM, Kakkar TL, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. <i>Semin Thromb Hemost</i> 2014;40(7):724–735	2014
17	Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. <i>Semin Thromb Hemost</i> 2014;40(3):277–283	2014
18	Favaloro EJ. Clinical utility of the PFA-100. <i>Semin Thromb Hemost</i> 2008;34(8):709–733	2008
19	Althaus K, Greinacher A. MYH9-related platelet disorders. <i>Semin Thromb Hemost</i> 2009;35(2):189–203. OA	2009
20	Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). <i>Semin Thromb Hemost</i> 2014;40(4):416–421	2014

(Continued)

Table 3 (Continued)

Rank	Citation	Year of publication
21	Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. <i>Semin Thromb Hemost</i> 2011;37(7):802–809	2011
22	Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? <i>Semin Thromb Hemost</i> 2015;41(4):395–404	2015
23	Hylek EM. Anticoagulation therapy for atrial fibrillation. <i>Semin Thromb Hemost</i> 2013;39(2):147–152	2013
24	Nurden AT. Platelet membrane glycoproteins: a historical review. <i>Semin Thromb Hemost</i> 2014;40(5):577–584	2014
25	Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. <i>Semin Thromb Hemost</i> 2014;40(1):121–128	2014
26	Salmela B, Joutsen-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23–30	2012
27	Italiano JE Jr. Unraveling mechanisms that control platelet production. <i>Semin Thromb Hemost</i> 2013;39(1):15–24	2013
28	Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. <i>Semin Thromb Hemost</i> 2008;34(8):772–778	2008
29	Harenberg J, Kraemer S, Du S, Giese C, Schulze A, Kraemer R, Weiss C. Determination of direct oral anticoagulants from human serum samples. <i>Semin Thromb Hemost</i> 2014;40(1):129–134	2014
30	Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. <i>Semin Thromb Hemost</i> 2008;34(1):58–73	2008
31	Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. <i>Semin Thromb Hemost</i> 2015;41(2):228–236	2015
32	Schulman S. Update on the treatment of venous thromboembolism. <i>Semin Thromb Hemost</i> 2016;42(8):891–898	2016
33	Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. <i>Semin Thromb Hemost</i> 2015;41(1):68–74	2015
34	Zolfaghari S, Harenberg J, Frölich L, Weiss C, Wehling M, Wild P, Prochaska J, Beyer-Westendorf J, Koscielny J, Lip GY. Development of recommendations to continue anticoagulation with one of the two types of oral anticoagulants based on the identification of patients' preference. <i>Semin Thromb Hemost</i> 2015;41(2):166–177	2015
35	Tapson VF. Thrombolytic therapy for acute pulmonary embolism. <i>Semin Thromb Hemost</i> 2013;39(4):452–458	2013
36	Elewa H, Ahmed D, Barnes GD. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting: searching for the best combination. <i>Semin Thromb Hemost</i> 2016;42(6):662–670	2016
37	Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. <i>Semin Thromb Hemost</i> 2008;34(1):86–96	2008
38	Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. <i>Semin Thromb Hemost</i> 2006;32(8):803–809	2006
39	Levi M, Poll TV. Coagulation in patients with severe sepsis. <i>Semin Thromb Hemost</i> 2015;41(1):9–15	2015
40	Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. <i>Semin Thromb Hemost</i> 2009;35(5):515–524	2009
41	Tersteeg C, Fijnheer R, Pasterkamp G, de Groot PG, Vanhoorelbeke K, de Maat S, Maas C. Keeping von Willebrand factor under control: alternatives for ADAMTS13. <i>Semin Thromb Hemost</i> 2016;42(1):9–17	2016
42	Mammen EF. Sticky platelet syndrome. <i>Semin Thromb Hemost</i> 1999;25(4):361–365	1999
43	Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. <i>Semin Thromb Hemost</i> 2008;34(1):39–57	2008
44	Kwaan HC. From fibrinolysis to the plasminogen-plasmin system and beyond: a remarkable growth of knowledge, with personal observations on the history of fibrinolysis. <i>Semin Thromb Hemost</i> 2014;40(5):585–591	2014
45	Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement. <i>Semin Thromb Hemost</i> 2016;42(5):526–532	2016

^aTable data derived from download information provided by the publisher of STH, Thieme, accordant ranking of downloads and year of publication. Date range of publications 1999–2016. Table includes full length papers only, and excludes Prefaces/Editorials/Letters/Correspondence.

have an advantage over those published later in timeline in terms of “total download timeline opportunity.” Not unexpectedly, many of the papers in ►Tables 1 and 2 do not appear in ►Tables 3 and 4. This most likely relates to the timeline of data capture, with data in ►Tables 3 and 4 being most contemporary, and that in ►Tables 1 and 2 providing a more relevant historical context for this editorial.

Notwithstanding anything already mentioned, and recognizing that these listings will not capture all contributions to STH, sincere gratitude is expressed to all contributors to this journal over the past 45 years, as well as our readership past and present. You all share in a unique history. On a personal note, I expect to be around to celebrate the 50th year anniversary of STH in 2024. I doubt whether I will be around

Table 4 The top 45 most downloaded “not free to download/open access” full papers published in *Seminars in Thrombosis and Hemostasis* during the period 2014–2017 inclusive^a

Rank	Citation	Year of publication
1	Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. <i>Semin Thromb Hemost</i> 2003;29(5):435–450	2003
2	Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremaux-Bacchi V, Licht C. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. <i>Semin Thromb Hemost</i> 2014;40(4):444–464	2014
3	Duga S, Salomon O. Congenital factor XI deficiency: an update. <i>Semin Thromb Hemost</i> 2013;39(6):621–631	2013
4	Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. <i>Semin Thromb Hemost</i> 2004;30(5):579–589	2004
5	Senoo K, Lip GY. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. <i>Semin Thromb Hemost</i> 2015;41(2):146–153	2015
6	Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. <i>Semin Thromb Hemost</i> 2013;39(7):772–778	2013
7	Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation. <i>Semin Thromb Hemost</i> 2015;41(5):527–537	2015
8	Vivarelli M, Emma F. Treatment of c3 glomerulopathy with complement blockers. <i>Semin Thromb Hemost</i> 2014;40(4):472–477	2014
9	Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). <i>Semin Thromb Hemost</i> 2014;40(4):422–430	2014
10	Scharf RE. Drugs that affect platelet function. <i>Semin Thromb Hemost</i> 2012;38(8):865–883	2012
11	Davie EW, Kulman JD. An overview of the structure and function of thrombin. <i>Semin Thromb Hemost</i> 2006;32(Suppl 1):3–15	2006
12	Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? <i>Semin Thromb Hemost</i> 2014;40(7):756–765	2014
13	Xiao X, Pickering MC, Smith RJ. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and c3 glomerulonephritis. <i>Semin Thromb Hemost</i> 2014;40(4):465–471	2014
14	Barbano B, Gigante A, Amoroso A, Cianci R. Thrombosis in nephrotic syndrome. <i>Semin Thromb Hemost</i> 2013;39(5):469–476	2013
15	Menegatti M, Peyvandi F. Factor X deficiency. <i>Semin Thromb Hemost</i> 2009;35(4):407–415	2009
16	Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. <i>Semin Thromb Hemost</i> 2002;28(3):247–256	2002
17	Knöbl P. Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. <i>Semin Thromb Hemost</i> 2014;40(4):493–502	2014
18	McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. <i>Semin Thromb Hemost</i> 2015;41(3):300–314	2015
19	Franchini M, Mannucci PM. The history of hemophilia. <i>Semin Thromb Hemost</i> 2014;40(5):571–576	2014
20	Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. <i>Semin Thromb Hemost</i> 2014;40(3):325–331	2014
21	Ranucci M. Hemostatic and thrombotic issues in cardiac surgery. <i>Semin Thromb Hemost</i> 2015;41(1):84–90	2015
22	Agno W, Riva N, Schulman S, Bang SM, Sartori MT, Grandone E, Beyer-Westendorf J, Barillari G, Di Minno MN, Dentali F, IRSVT Study Group. Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. <i>Semin Thromb Hemost</i> 2014;40(1):99–105	2014
23	Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. <i>Semin Thromb Hemost</i> 2013;39(5):559–566	2013
24	O'Brien SH. Contraception-related venous thromboembolism in adolescents. <i>Semin Thromb Hemost</i> 2014;40(1):66–71	2014
25	Andrews RK, Berndt MC. Bernard-Soulier syndrome: an update. <i>Semin Thromb Hemost</i> 2013;39(6):656–662	2013
26	McMahon BJ, Kwaan HC. The new or non-vitamin K antagonist oral anticoagulants: what have we learned since their debut. <i>Semin Thromb Hemost</i> 2015;41(2):188–194	2015
27	Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. <i>Semin Thromb Hemost</i> 2003;29(5):467–471	2003
28	Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world—a problem or a myth? <i>Semin Thromb Hemost</i> 2014;40(8):852–859	2014
29	Linnemann B. Management of complications related to central venous catheters in cancer patients: an update. <i>Semin Thromb Hemost</i> 2014;40(3):382–394	2014
30	Semeraro N, Ammollo CT, Semeraro F, Colucci M. Coagulopathy of acute sepsis. <i>Semin Thromb Hemost</i> 2015;41(6):650–658	2015
31	Boedeker BG. Production processes of licensed recombinant factor VIII preparations. <i>Semin Thromb Hemost</i> 2001;27(4):385–394	2001
32	Franchini M, Coppola A, Rocino A, Santagostino E, Tagliaferri A, Zanon E, Morfini M; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update. <i>Semin Thromb Hemost</i> 2013;39(7):752–766	2013

(Continued)

Table 4 (Continued)

Rank	Citation	Year of publication
33	Roberts LN, Bernal W. Management of Bleeding and Thrombosis in Critically Ill Patients with Liver Disease. <i>Semin Thromb Hemost</i> 2015;41(5):520–526	2015
34	McEwen BJ. The influence of diet and nutrients on platelet function. <i>Semin Thromb Hemost</i> 2014;40(2):214–226	2014
35	Gando S. Hemostasis and thrombosis in trauma patients. <i>Semin Thromb Hemost</i> 2015;41(1):26–34	2015
36	Hellgren M. Hemostasis during normal pregnancy and puerperium. <i>Semin Thromb Hemost</i> 2003;29(2):125–130	2003
37	Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. <i>Semin Thromb Hemost</i> 2006;32(Suppl 1):32–38	2006
38	Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. <i>Semin Thromb Hemost</i> 2013;39(2):191–201	2013
39	Lim W. Thrombotic risk in the antiphospholipid syndrome. <i>Semin Thromb Hemost</i> 2014;40(7):741–746	2014
40	Gremmel T, Frelinger AL III, Michelson AD. Platelet physiology. <i>Semin Thromb Hemost</i> 2016;42(3):191–204	2016
41	Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. <i>Semin Thromb Hemost</i> 2010;36(8):807–818	2010
42	Kumar R, Dunn A, Carcao M. Changing paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. <i>Semin Thromb Hemost</i> 2016;42(1):18–29	2016
43	Schroeder V, Kohler HP. Factor XIII deficiency: an update. <i>Semin Thromb Hemost</i> 2013;39(6):632–641	2013
44	Pavlova A, Oldenburg J. Defining severity of hemophilia: more than factor levels. <i>Semin Thromb Hemost</i> 2013;39(7):702–710	2013
45	Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. <i>Semin Thromb Hemost</i> 2011;37(3):237–251	2011

^aTable data derived from download information provided by the publisher of STH, Thieme, accordant ranking of downloads, and year of publication. Date range of publications 2001–2016. Table includes full length papers only, and excludes Prefaces/Editorials/Letters/Correspondence.

to share in the 100th year anniversary of STH, although I do hope that STH manages to celebrate this future milestone. I may even be remembered fondly on that occasion.

References

- Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). Special issue. *Semin Thromb Hemost* 2008;34(08):693–794
- Favaloro EJ. A short history of Thrombosis and Hemostasis: part I (40th year celebratory issue). *Semin Thromb Hemost* 2014;40(05):521–525
- Favaloro EJ. A short history of thrombosis and hemostasis: part II (40th year celebratory issue). *Semin Thromb Hemost* 2014;40(08):826–830
- Favaloro EJ. Editorial – 2018 Eberhard F Mammen award announcements: Part I – Most popular articles. *Semin Thromb Hemost* 2018;44(03):185–192
- Favaloro EJ. Welcome to Seminars in Thrombosis & Hemostasis 2018. New (2016) impact factor and most highly cited papers. *Semin Thromb Hemost* 2018;44(01):1–4
- Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. *Semin Thromb Hemost* 2008;34(01):7–25
- Rodgers RP, Levin J. A critical reappraisal of the bleeding time. *Semin Thromb Hemost* 1990;16(01):1–20
- Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. *Semin Thromb Hemost* 1998;24(02):195–202
- Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer–PFA-100. *Semin Thromb Hemost* 1995;21(Suppl 2):106–112
- Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. *Semin Thromb Hemost* 1995;21(Suppl 2):113–121
- Favaloro EJ. Clinical utility of the PFA-100. *Semin Thromb Hemost* 2008;34(08):709–733
- Favaloro EJ. Clinical utility of closure times using the platelet function analyzer-100/200. *Am J Hematol* 2017;92(04):398–404
- Franchini M, Lippi G, Favaloro EJ. Dedication. Rodger L. Bick, M.D., Ph.D., FACP (1943–2008). *Semin Thromb Hemost* 2009;35:255–256
- Harris EN, Willis R. Silvia Pierangeli, PhD (1955–2013). *Semin Thromb Hemost* 2014;40(02):137–139
- White GC II, Blatt PM. Harold Ross Roberts, M.D: inspirational mentor, consummate physician, superb scientist (1930–2017). *J Thromb Haemost* 2017;15(12):2468–2470
- Jurk K, Kehrel BE. Platelets: physiology and biochemistry. *Semin Thromb Hemost* 2005;31(04):381–392
- Favaloro EJ. Editorial. Winners of the Inaugural Eberhard F. Mammen Award for Most Popular Article. *Semin Thromb Hemost* 2009;35:587–590
- Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. *Semin Thromb Hemost* 2008;34(03):236–250